HD-OPM Archive

Colchicine and anti-inflammatory therapy for the heart

Why inflammation is now treated as a real driver of heart attacks, what the group has shared about low-dose colchicine (approval, plaque imaging, mechanisms), how it compares with other anti-inflammatory strategies, and who the admins think might benefit.

13 min read32 group posts cited41 studies discussed3 chartsEvidence through Oct 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • Low-dose colchicine (0.5 mg daily in the plaque-imaging study) is described in the group as the first drug approved to cut heart disease risk by targeting inflammation, with a label covering established atherosclerotic disease and people with multiple risk factors.
  • In a small randomized CT-angiography trial led by Matthew Budoff, colchicine 0.5 mg daily lowered percent atheroma volume by over 1% in one year and significantly lowered CRP.
  • A 2025 ACC Scientific Statement recommends universal hsCRP screening alongside cholesterol; hsCRP below 1 mg/L is lower risk and above 3 mg/L is higher risk.
  • Blocking one inflammatory molecule is not enough: the IL-6 blocker ziltivekimab lowered hsCRP and IL-6 in the ZEUS trial but did not reduce heart attacks, strokes or cardiovascular deaths.
  • Statins, ezetimibe, bempedoic acid and other lipid drugs also lower hsCRP (statins about 17%), so colchicine is an add-on to, not a replacement for, LDL lowering.
  • The group's admins discuss colchicine as something to raise with your own doctor, particularly for people with established disease or a high residual inflammatory risk.
In this summary
  1. Why inflammation matters for the heart
  2. What the colchicine evidence shows
  3. Other anti-inflammatory strategies and what the group makes of them
  4. What this means for you
  5. Frequently asked questions
  6. The evidence behind this summary

Inflammation is the immune system's alarm response. When it is short-lived, as with a twisted ankle or a mild flu, it is part of healing; when it smolders for years it can damage tissue silently, and it has been linked to heart disease, among other conditions.1 The group's view, echoed by several heart specialists whose work members have shared, is that chronic arterial inflammation is not a side effect of atherosclerosis (plaque build-up in the artery walls) but one of its drivers.23

Colchicine is the drug at the centre of this idea. Louis Nervegna describes it as the first drug approved to treat heart disease by targeting inflammation.4 It has FDA approval for lowering cardiovascular events, and the approval language he shared covers people with established atherosclerotic disease and also those with multiple risk factors.5 This article explains what the group has posted about the drug, how that fits with the wider inflammation story (including a notable failure), and what the admins suggest for practical decision-making. It is a summary of group discussion, not medical advice.

0.5 mgdaily colchicine, the dose used in the plaque-imaging trial6
1%and more: the fall in percent atheroma volume on colchicine in one year6
15%fewer major cardiovascular events when CANTOS blocked IL-1 beta7
3 mg/LhsCRP above this level means higher relative risk (2025 ACC statement)2

Why inflammation matters for the heart

Cholesterol lights the match, immune cells fan the fire

A Scientific American article that Louis endorsed, built on the work of Harvard's Paul Ridker, explains the current thinking. Cholesterol that builds up in the artery wall takes a crystal-like form that the immune system does not recognize, and the resulting immune attack on the vessel is what ultimately leads to heart attacks and strokes.3 The same article notes that cholesterol is therefore the match that lights the fire of vascular inflammation rather than a minor player.3

Another member-shared overview describes the central pathway. Danger signals such as cholesterol crystals activate the NLRP3 inflammasome (a protein complex in immune cells), which releases the cytokine IL-1 beta. IL-1 beta drives IL-6, and IL-6 makes the liver produce C-reactive protein (CRP).7 The same post reports that the CANTOS trial, which blocked IL-1 beta with the drug canakinumab, produced a 15% reduction in major cardiovascular events in high-risk patients.7 Peter Libby, in a talk summarized in the group, also pointed to canakinumab and colchicine as therapies that have shown cardiovascular benefit.10

Residual inflammatory risk

Many people are on a statin with low LDL and still have heart attacks. Ridker's phrase, quoted in a post by Louis, is that "you're not home free": even with low LDL on a statin you may carry inflammatory risk.11 That is called residual inflammatory risk. In the Scientific American excerpt, the JUPITER trial enrolled nearly 18,000 people with low LDL but high CRP; those on a statin had 54% fewer heart attacks and 48% fewer strokes, and the trial was stopped early.3 Louis argues that inflammation is largely independent of classical risk factors such as LDL, blood pressure, diabetes and smoking, so it can keep driving disease even when those are well managed.3

Treating inflammation-linked risk cut eventsRelative reduction in events in two trials discussed in the group
JUPITER (statin): heart attacks54% fewer
JUPITER (statin): strokes48% fewer
CANTOS (canakinumab): major cardiovascular events15% fewer
Different drugs and populations: JUPITER gave a statin to nearly 18,000 people with low LDL but high CRP (stopped early); CANTOS gave canakinumab, an IL-1 beta blocker, to high-risk patients. Source: 37
Show data
Value
JUPITER (statin): heart attacks54% fewer
JUPITER (statin): strokes48% fewer
CANTOS (canakinumab): major cardiovascular events15% fewer

Not everyone agrees on emphasis. In a debate summarized by Gokhan Can, Libby argued that substantial inflammatory risk remains with well-controlled LDL, and that IL-6 plays a causal role. Derick Raal argued that LDL is the primary cause and inflammation largely a consequence, best handled by earlier, more aggressive LDL lowering plus lifestyle and weight loss. Both agreed there is value in addressing both.12

Measuring inflammation: hsCRP and beyond

The 2025 American College of Cardiology Scientific Statement, summarized by Gokhan, calls inflammation a clinically actionable risk factor and recommends universal screening with high-sensitivity CRP (hsCRP) alongside cholesterol assessment, in both primary prevention (no known disease) and secondary prevention (existing disease).2 The thresholds it restates are:

  • below 1 mg/L: lower relative risk
  • 1 to 3 mg/L: average relative risk
  • above 3 mg/L: higher relative risk2

The statement cites a 30-year study of nearly 28,000 women in which a single hsCRP measurement spread future risk more widely than LDL or lipoprotein(a), and a meta-analysis of over 160,000 people in which each one-standard-deviation rise in hsCRP went with a 37% higher risk of coronary heart disease and a 55% higher risk of cardiovascular death.2 IL-6 and fibrinogen also predict risk, and a CT-based measure called the perivascular fat attenuation index is described as promising but not routine.2

Higher hsCRP, higher riskHigher risk per one-standard-deviation rise in hsCRP, meta-analysis of over 160,000 people cited in the 2025 ACC statement
Coronary heart disease37% higher
Cardiovascular death55% higher
Observational association. Source: 2
Show data
Value
Coronary heart disease37% higher
Cardiovascular death55% higher

A case shared in the group shows the limits of a blood test. After aggressive lipid lowering (LDL 35-50 mg/dL) his stenosis fell from 70% to under 25%, and his hsCRP was only 0.15 mg/L, yet an AI analysis of his CT angiogram (CaRi-Heart) reported a high coronary fat attenuation score of 8.1 in the LAD artery, at the 93rd percentile for his age and sex. Louis describes that CT-based approach as probably the most accurate non-invasive way to estimate residual inflammatory risk, and he tags it with colchicine.13 This is a single case and a commercial tool, so it is best read as an illustration rather than a validated pathway.

The CaRi-Heart report from the case Louis shared: fat attenuation (FAI) scores by coronary artery plotted against age-and-sex percentile curves, with 8.1 in the left anterior descending artery (93rd percentile), 5.4 in the left circumflex (55th) and 6.6 in the right coronary artery (74th).
The CaRi-Heart report from the case Louis shared: fat attenuation (FAI) scores by coronary artery plotted against age-and-sex percentile curves, with 8.1 in the left anterior descending artery (93rd percentile), 5.4 in the left circumflex (55th) and 6.6 in the right coronary artery (74th).13

What the colchicine evidence shows

Approval and the outcome story

The group's posts treat colchicine's approval as the practical turning point. Louis writes that it has full FDA approval to treat heart disease, even for primary prevention, working by lowering arterial inflammation.5 The Scientific American piece states that the FDA approved colchicine in 2023 to reduce heart attack and related risk, based in part on the inflammation research described above.3 A separate post lists "ten game-changing" cardiology trials and calls number ten the first major trial showing that lowering arterial inflammation reduces heart attacks and strokes, which Louis argues proved inflammation is causal; he tagged that post with colchicine, though the linked list is no longer available.14

Gokhan flagged a Circulation editorial saying that affordable, widely available colchicine shows promise in reducing atherothrombotic risk in ASCVD (atherosclerotic cardiovascular disease) by stabilizing coronary plaques and reducing inflammation. His own reaction: "This sounds very big."15 A Heart journal podcast shared by Louis discusses the imaging substudy of the LoDoCo2 trial, which tested colchicine in patients with chronic coronary syndromes, and how colchicine affects inflammation in the coronary arteries; the post gives no results.16

The Budoff plaque-imaging trial

The most detailed colchicine data in the group concern plaque. In the trial Louis highlighted, patients were randomized to colchicine 0.5 mg daily or placebo and had CT angiography at baseline and after one year. Matthew Budoff reported more than a 1% reduction in percent atheroma volume (PAV, the share of the artery wall volume occupied by plaque) in the colchicine group, a size of change he said mirrors what earlier intravascular ultrasound studies linked to significant reductions in major cardiovascular events.6 There was also a significant fall in CRP, trends toward regression of non-calcified, fibro-fatty and fibrous plaque, and a significant slowing of calcified plaque progression.6

Budoff himself stressed it was a relatively small, one-year study, though he said it supports using colchicine in chronic stable coronary disease.6 Louis contrasts it with the Keto-CTA study from the same investigator, where PAV rose 0.8% on a ketogenic diet.6

Gokhan's earlier plaque summary gave a more cautious read. He rates colchicine "likely helpful" for plaque and cites an open-label CT angiography study in which 0.5 mg per day reduced low-attenuation (soft, lipid-rich) plaque volume compared with optimal medical therapy alone over 12 months, while total atheroma volume changes were similar. He says further imaging RCTs are needed even though clinical outcome data are promising.8 In the same post, statins, PCSK9 inhibitors and ezetimibe are ranked as having the strongest plaque evidence.8

Louis counts colchicine among at least six strategies shown to reverse plaque in human randomized trials, alongside major weight loss, Mediterranean or DASH diets, LDL-lowering drugs, exercise and high-dose EPA fish oil, and says he would love to see a trial combining them all.1718 He also points to the earlier posts describing the randomized colchicine trial.19 Because the evidence base for colchicine plaque regression is small compared with that for statins, these are claims to weigh carefully rather than settled fact.

Possible mechanisms beyond general inflammation

  • IL-11 (speculative). Louis notes colchicine has anti-fibrotic properties and was once studied in pulmonary fibrosis, and he speculates it may work partly by inhibiting IL-11, a cytokine whose blockade extended mouse lifespan by about 25%. He labels this a hypothesis.420
  • TET2 clonal hematopoiesis. Clonal hematopoiesis (CHIP) refers to acquired mutations in blood stem cells and was reported in the PESA-CNIC-Santander study to precede and raise atherosclerosis risk. In a related European Heart Journal study, colchicine slowed atherosclerosis in animals with TET2 mutations, and people with TET2 mutations treated with colchicine for other conditions had a lower risk of heart attack. These findings suggest a possible personalized approach but are early.21

Other anti-inflammatory strategies and what the group makes of them

Lipid drugs also lower inflammation

Louis summarizes meta-analysis data on average hsCRP reductions: statins 17.3%, bempedoic acid 20%, fibrates 10.3%, ezetimibe 3.2%, with fish oil about 12.8%; he also lists PCSK9 inhibitors at 6%. The paper's own illustration, shared in the same post, shows PCSK9 inhibitors slightly raising hsCRP (about +6%) rather than lowering it, and the fibrate reduction as not statistically significant.22 Part of this, he says, is that LDL itself is inflammatory once it oxidizes inside the artery wall.22 Gokhan's earlier post on the same Cardiovascular Research meta-analysis notes that the effect is independent of LDL reduction and adds colchicine, GLP-1 receptor agonists and low-dose pioglitazone to the list of other options to consider.23 Ezetimibe added to a statin gave a significant extra 10% CRP reduction in a pooled analysis.24 In the PROVE IT-TIMI 22 trial, atorvastatin 80 mg cut 30-day death, heart attack or rehospitalization (3.0% versus 4.2%), an early effect Louis attributes at least partly to anti-inflammatory and plaque-stabilizing actions, while noting others argue lower LDL itself accounts for some of it.25

Lipid drugs lower hsCRP too, by very different amountsAverage hsCRP reduction by drug class, as listed by Louis from a meta-analysis
Bempedoic acid20%
Statins17.3%
Fish oil12.8%
Fibrates10.3%
PCSK9 inhibitors6%
Ezetimibe3.2%
Averages across different trials, not head-to-head comparisons. Source: 22
Show data
Value
Bempedoic acid20%
Statins17.3%
Fish oil12.8%
Fibrates10.3%
PCSK9 inhibitors6%
Ezetimibe3.2%

Canakinumab and the IL-6 disappointment

In the COSMOS trial of canakinumab plus rosuvastatin 40 mg (not to be confused with the cocoa trial of the same name), PAV fell 0.95% versus 0.05% with placebo over 52 weeks in 418 patients.26

The ZEUS trial of ziltivekimab (an IL-6 blocker) is the cautionary example. It lowered hsCRP and IL-6 as designed, but heart attacks, strokes and cardiovascular deaths matched placebo, with more serious infections.9 Louis concludes that IL-6 now looks like a marker rather than a cause, similar to HDL, and that the overall inflammatory pattern is what matters; diet and colchicine, he argues, address that wider pattern.9 The commentary shared alongside the post offered another possibility: that in patients whose LDL was already low there may have been less room to see benefit.9 Louis adds that the interventions that have worked best, such as statins and diet, tackle upstream causes of inflammation, whereas NSAIDs and corticosteroids lower hsCRP downstream yet make heart disease worse.27

The ZEUS summary graphic shared in the group: in 6,376 people with atherosclerotic disease, chronic kidney disease and hsCRP of 2 mg/L or more, ziltivekimab lowered hsCRP and IL-6 but not heart attacks, strokes or cardiovascular deaths (hazard ratio 0.99, 95% CI 0.88 to 1.11), with more serious infections.
The ZEUS summary graphic shared in the group: in 6,376 people with atherosclerotic disease, chronic kidney disease and hsCRP of 2 mg/L or more, ziltivekimab lowered hsCRP and IL-6 but not heart attacks, strokes or cardiovascular deaths (hazard ratio 0.99, 95% CI 0.88 to 1.11), with more serious infections.9

Diet, supplements and other drugs

Gokhan keeps a personal list of anti-inflammatory agents he has used (curcumin, fish oil, aspirin, rosuvastatin and others) and wrote that he wanted to try low-dose colchicine; it is an experiment list, not trial evidence, and he notes aspirin carries bleeding risk and needs medical supervision.28 Louis also names a "lower the whole inflammatory pattern" approach through the Mediterranean diet and exercise.2027 Posts on SGLT2 inhibitors describe anti-inflammatory vascular effects (lower TNF, IL-6, MCP-1), though one empagliflozin finding was a small pilot.2930 The Scientific American supplement article, as shared, warns that most anti-inflammatory supplements lack solid evidence.1 Louis also argues that more than 30 human trials show omega-6 oils from nuts and seeds do not raise inflammatory markers.3132

What this means for you

  • Ask about inflammation, not just LDL. The ACC statement recommends hsCRP alongside cholesterol, and the group's admins suggest knowing your number (below 1 is lower risk, above 3 is higher).2
  • Colchicine sits on top of LDL lowering. The group's plaque-regression posts rank statins, PCSK9 inhibitors and ezetimibe as having the strongest evidence, and colchicine as promising and approved.817
  • The approval covers established disease and some people with multiple risk factors. Whether it suits you is a conversation for your cardiologist.5
  • Remember the dose studied. The plaque trial used 0.5 mg daily.6 The group's posts concentrate on benefit; side effects and medication interactions are worth discussing with a prescriber.
  • Do not self-treat with NSAIDs or steroids. They lower CRP but, per Louis, make heart disease worse.27
  • Be cautious with imaging add-ons and supplements. CT inflammation scores such as CaRi-Heart are newer and shown here by a single case.13
  • Do not drop the basics. Louis argues diet and exercise remain the best way to address upstream causes of inflammation.27

Frequently asked questions

Is colchicine approved for heart disease?

Yes. Louis states it has full FDA approval, including for primary prevention in people with multiple risk factors.5 The Scientific American article dates the approval to 2023.3

What dose was used in the plaque study?

Colchicine 0.5 mg daily versus placebo, with CT angiography at baseline and one year.6 Gokhan's summary of an open-label study also used 0.5 mg per day.8

Does colchicine shrink plaque?

One randomized CT trial reported more than a 1% fall in PAV and trends toward regression of several plaque types in a year; Budoff called it small.6 Gokhan rates it "likely helpful" and asks for larger imaging trials.8

Why did the IL-6 drug fail if inflammation matters?

Louis argues IL-6 is a marker of a broader inflammatory pattern, and that colchicine and diet work because they address that broader pattern.9 The commentary shared with the post suggested low baseline LDL may have limited the visible benefit.9

Should everyone test hsCRP?

The 2025 ACC statement recommends universal screening.2 Louis cautions that hsCRP can be low while CT-measured coronary inflammation is high, so a single number is not the whole picture.13

Could colchicine matter more for some genetic groups?

Early work links TET2 clonal hematopoiesis mutations with benefit from colchicine in animals and observational human data, but this is a hypothesis-generating finding.21

The evidence behind this summary41 studies · 2 meta-analyses · 23 trials · 4 observational

The 32 group posts cited above discuss 41 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 2Randomized trials 23Observational studies 4Reviews & guidelines 3Animal & lab studies 1Other sources 8

Strongest evidence discussed

All 41 studies and sources
Sources from the group (32)
  1. Scientific American: chronic low-grade inflammation and anti-inflammatory supplements Louis Nervegna · Mar 05, 2026 · Facebook
  2. 2025 ACC statement: inflammation is actionable in CVD, with universal hsCRP screening Gokhan Can · Oct 09, 2025 · Facebook
  3. Scientific American: inflammation is a heart risk factor independent of LDL, BP, diabetes Louis Nervegna · Apr 18, 2026 · Facebook
  4. Colchicine may work partly by inhibiting IL-11, a lifespan-linked pro-fibrotic cytokine Louis Nervegna · Jul 26, 2024 · Facebook
  5. FDA approved low-dose colchicine for CV risk reduction, including multiple risk factors Louis Nervegna · Jun 20, 2025 · Facebook
  6. Colchicine 0.5 mg cut plaque volume by over 1% in one year on CT angiography (Budoff) Louis Nervegna · May 11, 2025 · Facebook
  7. Non-traditional heart disease risk factors converge on inflammation and oxidative stress Gokhan Can · Aug 29, 2025 · Facebook
  8. Plaque reduction: statins, PCSK9 inhibitors and ezetimibe have the strongest evidence Gokhan Can · May 18, 2024 · Facebook
  9. ZEUS: ziltivekimab cut hsCRP and IL-6 but did not reduce cardiovascular events Louis Nervegna · Aug 01, 2026 · Facebook
  10. Peter Libby on inflammation in atherosclerosis, CHIP, canakinumab and colchicine Gokhan Can · Feb 17, 2024 · Facebook
  11. Inflammation is a causal risk factor; CRP predicts heart disease as well as LDL (Ridker) Louis Nervegna · Jun 20, 2025 · Facebook
  12. Libby vs Raal debate: is inflammation or LDL the key driver of CVD risk? Gokhan Can · Oct 19, 2024 · Facebook
  13. CaRi-Heart AI on CT angiograms measures coronary inflammation missed by hs-CRP Louis Nervegna · Sep 18, 2026 · Facebook
  14. Ten game-changing recent cardiology RCTs, incl. the one showing inflammation is causal Louis Nervegna · Jul 21, 2025 · Facebook
  15. Colchicine may stabilize plaques and cut atherothrombotic risk: Circulation editorial Gokhan Can · Sep 27, 2024 · Facebook
  16. Heart podcast on the LoDoCo2 imaging substudy of colchicine and coronary inflammation Louis Nervegna · Oct 04, 2026 · Facebook
  17. Six strategies shown to regress plaque in human randomized trials Louis Nervegna · Feb 27, 2025 · Facebook
  18. At least six strategies have reversed plaque in randomized trials Louis Nervegna · Aug 12, 2026 · Facebook
  19. Plaque regression is real: Louis links the randomized trials of drugs, colchicine and EPA Louis Nervegna · Sep 05, 2026 · Facebook
  20. Blocking IL-11 extended mouse lifespan ~25%; diets and drugs that may lower it listed Louis Nervegna · Jul 17, 2024 · Facebook
  21. Clonal hematopoiesis (CHIP) mutations precede and raise atherosclerosis risk in PESA study Gokhan Can · Sep 05, 2024 · Facebook
  22. Statins, bempedoic acid, ezetimibe, fibrates and PCSK9 inhibitors all lower hsCRP Louis Nervegna · Dec 28, 2025 · Facebook
  23. Meta-analysis: statins, bempedoic acid, ezetimibe and omega-3 lower CRP independent of LDL Gokhan Can · Feb 19, 2024 · Facebook
  24. Adding ezetimibe to a statin lowers CRP by an extra 10% in pooled trials Gokhan Can · Nov 09, 2024 · Facebook
  25. PROVE IT-TIMI 22: atorvastatin 80 mg early after a heart attack cut 30-day events 28% Louis Nervegna · Jul 31, 2024 · Facebook
  26. Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS Louis Nervegna · Jan 18, 2025 · Facebook
  27. Statins may lower hsCRP by stabilizing plaque; fixing upstream causes beats blocking IL-6 Louis Nervegna · Aug 10, 2026 · Facebook
  28. A personal list of anti-inflammatory drugs and supplements, with low-dose colchicine next Gokhan Can · Feb 18, 2024 · Facebook
  29. SGLT2 inhibitors protect heart and kidneys via vascular and anti-inflammatory effects Louis Nervegna · Jan 23, 2026 · Facebook
  30. Empagliflozin reduced monocyte-platelet aggregates, hinting at vascular anti-inflammation Louis Nervegna · Oct 23, 2026 · Facebook
  31. Soybean oil 30 g/day lowered arachidonic acid in a 2026 trial; 30+ RCTs: not inflammatory Louis Nervegna · Oct 22, 2026 · Facebook
  32. Over 30 randomized trials find omega-6 linoleic acid does not raise inflammation markers Louis Nervegna · Oct 05, 2026 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary